Considerations for Oncology Pharmacists Managing Patients on PARP Inhibitors
At the ESMO Congress 2019, Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital, discussed the role of oncology pharmacists in managing the treatment of patients with ovarian cancer.
I think the very important thing is that whatever of the PARP inhibitors available that are chosen by your doctors, you should make sure they are prescribing the right dose. For example, for niraparib, be aware that you should not give 300 mg capsules daily if a patient is less than 77 kg or had a baseline thrombocyte count of 150 or less, so in that case they should prescribe 2 capsules. So I think it is important that you secure the safety of the patient in such a manner, and the same is the case for other treatments, that you make sure that patients receive the correct treatment.